domvanalimab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
domvanalimab

GtoPdb Ligand ID: 13983

Synonyms: AB-154 | AB154

Compound class: Antibody

Comment: Domvanalimab (AB154) is an anti-TIGIT monoclonal antibody. It is designed to be 'Fc-silent' as a method to prevent depletiion of regulatory T cells (which would otherwise be promoted by Fc-mediated antibody dependent cellular cytotoxicity). Silencing TIGIT has two functions. It negates the inhibitory action of TIGIT binding to poliovirus receptor (PVR, CD155) which blocks immune suppression, and it leaves PVR available to interact with the costimulatory DNAM-1 (CD226) molecule. The combined effects potentiate a natural killer (NK) cell and T cell-mediated anti-tumour immune response.

References
1. Arcus Biosciences. ANTI-TIGIT - DOMVANALIMAB. Accessed on 09/07/2025. Modified on 09/07/2025. arcusbio.com, https://arcusbio.com/our-science/clinical-candidates/domvanalimab/
2. Hsiehchen D, Kainthla R, Kline H, Siglinsky E, Ahn C, Zhu H. (2025) Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial. Nat Commun, 16 (1): 5819. [PMID:40592848]
3. Rodriguez-Abreu D, Bosch-Barrera J, Gray JE, Ahn MJ, Johnson M, Yu X, Mohammad S, Chen X, Todd T, Kim J et al.. (2024) STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene Alterations. Clin Lung Cancer, 25 (3): 274-279. [PMID:38310035]

References

1. Arcus Biosciences.
ANTI-TIGIT - DOMVANALIMAB.
Accessed on 09/07/2025. Modified on 09/07/2025. arcusbio.com, https://arcusbio.com/our-science/clinical-candidates/domvanalimab/

2. Hsiehchen D, Kainthla R, Kline H, Siglinsky E, Ahn C, Zhu H. (2025)
Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial.
Nat Commun, 16 (1): 5819. [PMID:40592848]

3. Rodriguez-Abreu D, Bosch-Barrera J, Gray JE, Ahn MJ, Johnson M, Yu X, Mohammad S, Chen X, Todd T, Kim J et al.. (2024)
STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene Alterations.
Clin Lung Cancer, 25 (3): 274-279. [PMID:38310035]